Paul Boland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5310637/publications.pdf

Version: 2024-02-01

1684188 1474206 9 105 5 9 citations h-index g-index papers 9 9 9 168 citing authors docs citations times ranked all docs

#	Article	lF	CITATIONS
1	Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk. Clinical and Translational Science, 2021, 14, 354-361.	3.1	8
2	Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2021, 14, e009994.	3.9	17
3	Modifiable Risk Factors and Residual Risk Following Coronary Revascularization. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 1138-1152.	2.4	5
4	Evaluation of plasminogen activator inhibitor-1 as a biomarker of unplanned revascularization and major adverse cardiac events in coronary angiography and percutaneous coronary intervention. Thrombosis Research, 2020, 191, 125-133.	1.7	6
5	Physician prediction of 1-year mortality in the cardiac catheterization laboratory. Coronary Artery Disease, 2020, Publish Ahead of Print, 403-410.	0.7	2
6	Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations. Journal of the American Heart Association, 2019, 8, e012228.	3.7	27
7	The Current Role of Viability Imaging to Guide Revascularization and Therapy Decisions in Patients With Heart Failure and Reduced Left Ventricular Function. Canadian Journal of Cardiology, 2019, 35, 1015-1029.	1.7	17
8	Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y ₁₂ receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 543-553.	1.0	15
9	Adenosine as a Marker and Mediator of Cardiovascular Homeostasis: A Translational Perspective. Cardiovascular & Hematological Disorders Drug Targets, 2019, 19, 109-131.	0.7	8